section name header

Evidence summaries

Interventions for Erythema Nodosum Leprosum

Thalidomide and clofazimine may have some effect in the treatment of erythema nodosum leprosum. Level of evidence: "C"

A Cochrane review [Abstract] 1 included 13 studies with a total of 445 subjects. Treatment of leprous erythema nodosum with thalidomide showed a significant remission of skin lesions compared to acetylsalicylic acid (aspirin) (RR 2.43; 95% CI 1.28 to 4.59) (1 trial, 92 participants). Clofazimine treatment was superior to prednisolone (more treatment successes; RR 3.67; 95% CI 1.36 to 9.91) (1 trial, 24 participants), and thalidomide (fewer recurrences; RR 0.08; 95% CI 0.01 to 0.56) (1 trial, 72 participants). No significant benefit was found for intravenous betamethasone compared to dextrose (1 trial, 10 participants), pentoxifylline compared to thalidomide (1 trial, 44 participants), indomethacin compared to prednisolone, aspirin or chloroquine treatments (2 trials, 80 participants), or levamisole compared to placebo (1 trial, 12 participants). Mild to moderate adverse events were significantly lower in participants taking 100 mg thalidomide compared to 300 mg thalidomide daily (RR 0.46; 95% CI 0.23 to 0.93). Significantly more minor adverse events were reported in participants taking clofazimine compared with prednisolone (RR 1.92; 95% CI 1.10 to 3.35). None of the studies assessed quality of life or economic outcomes.

Comment: The evidence is downgraded by study quality (inadequate or unclear allocation concealment, lack of blinding) and by imprecise results (limited study size for each comparison).

    References

    • Van Veen NH, Lockwood DN, van Brakel WH, Ramirez J Jr, Richardus JH. Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 2009 Jul 8;(3):CD006949. [PubMed]

Primary/Secondary Keywords